Overview of Dr. Ratain
Dr. Mark Ratain is an oncologist in Chicago, IL and is affiliated with University of Chicago Medical Center. He received his medical degree from Yale School of Medicine and has been in practice 37 years. Dr. Ratain accepts several types of health insurance, listed below. He is one of 123 doctors at University of Chicago Medical Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
5841 S. MARYLAND AVE.
M/C 2115
Chicago, IL 60637Fax+1 773-702-3969- Is this information wrong?
Education & Training
- University of ChicagoFellowship, Hematology and Medical Oncology, 1983 - 1986
- Johns Hopkins UniversityResidency, Internal Medicine, 1980 - 1983
- Yale School of MedicineClass of 1980
- Harvard UniversityA.B., Biochemical Sciences, Magna cum Laude
Certifications & Licensure
- IL State Medical License 1983 - 2026
- IN State Medical License 2023 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- American Board of Clinical PharmacologyClinical Pharmacology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- Chicago Magazine: Top Doctors Castle Connolly, 2004, 2006, 2008, 2010, 2012, 2014
- Spotlight on Science Featured Speaker American Society of Health System Pharmacists, 2013
- Join now to see all
Clinical Trials
- Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma Start of enrollment: 1996 Jun 01
- Carboxyamidotriazole and Ketoconazole in Treating Patients With Advanced Cancers Start of enrollment: 1998 May 01
- O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery Start of enrollment: 1999 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest?Austin Wesevich, Mark J Ratain> ;Nature Biotechnology. 2023 Nov 1
- Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?Mark J Ratain, Garth W Strohbehn> ;European Journal of Cancer. 2023 Nov 1
- Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?Austin Wesevich, Mark J Ratain> ;JAMA Oncology. 2023 Nov 1
- Join now to see all
Journal Articles
- Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19Mark J Ratain, Leonard B Saltz, JAMA Oncology
- A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer Using Genome‐Wide Genotyping Data from CALGB 40502 (Alliance)Hope S Rugo, Francisco Castillos, Beth Overmoyer, Mark J Ratain, Clinical Pharmacology & Therapeutics
- A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469Ramirez J, Kim TW, Liu W, Myers JL, Mirkov S, Owzar K, Watson D, Mulkey F, Gamazon ER, Stock W, Undevia S, Innocenti F, Ratain MJ, Pharmacogenet Genomics, 1/1/2014
- Join now to see all
Authored Content
- Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19May 2020
Press Mentions
- 203 UChicago Medicine Doctors Named to 2022 Top Docs ListJanuary 21st, 2022
- Why Did FDA Ask Amgen to Add Low-Dose Trial of Lumakras?November 1st, 2021
- Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan SafetyMarch 17th, 2021
- Join now to see all
Grant Support
- Phase I Clinical Trials Of Anti-Cancer AgentsNational Cancer Institute2003–2012
- Parent Project - Main Theme (MAIN)National Institute Of General Medical Sciences2010–2011
- Paar-Pharmacogenomics Of Anticancer Agents Research GroupNational Institute Of General Medical Sciences2010–2011
- Core V - Liver Tissue Core (LTC)National Institute Of General Medical Sciences2010–2011
- Core IV - Management And Administrative Core (MAC)National Institute Of General Medical Sciences2010–2011
- Clinical TherapeuticsNational Institute Of General Medical Sciences1992–2011
- Colorectal CancerNational Institute Of General Medical Sciences2005–2009
- Pharmacogenetics Of Anticancer Agents Research GroupNational Institute Of General Medical Sciences2000–2009
- Foreign Accrual For 5u10ca069852 - 2006 LoadNational Cancer Institute2006
- Sorafenib(Bay43-9006) And Blood PressureNational Center For Research Resources2005–2006
- AdministrativeNational Institute Of General Medical Sciences2005
- Core--Clinical Trial Protocol Review And Monitoring SystemNational Cancer Institute2002
- Glucuronidation (UGT) Of Sn38--Irinotecan ActivityNational Institute Of General Medical Sciences2000–2002
- Optimal 06-Benzylguanine Dose For DNA Alkyltransferase DepletionNational Center For Research Resources2000–2002
- Correlating UGT1A1 Genotype And Irinotecan Pharmacokinetics In Cancer PatientsNational Center For Research Resources2000–2002
- Cancer And Leukemia Group B--Pet CommitteeNational Cancer Institute1998–2002
- Phase I Trial Of ZD9331 As 30 MIN Infusion Daily For 5 DaysNational Center For Research Resources1997–2002
- Phase I Clinical Trials Of Anticancer AgentsNational Cancer Institute1995–2002
- Clinical And Experimental TherapeuticsNational Cancer Institute1996–2001
- Core--Pharmacology FacilityNational Cancer Institute1992–2001
- Cancer And Leukemia Group BNational Cancer Institute1995–1997
- Phase I &Clinical Pharmacokinetics--Anticancer AgentsDivision Of Cancer Treatment1994–1995
- Developmental TherapeuticsNational Cancer Institute1992–1995
- Phase I &Clinical Pharmacokinetics - Anti-Cancer AgentsDivision Of Cancer Treatment1991–1993
- Pharmacokinetics Of 4-Methyl-5-(2-Prazinyl)-1,2-Dithiol-3-Thione(Oltipraz)National Center For Research Resources1992
- Phase I &Clinical Pharmacokinetics--Anti-Cancer AgentDivision Of Cancer Treatment1990–1991
- Pharmacokinetic Analysis Of Continuous Intravenous Vinblastine InfusionNational Center For Research Resources1985–1987
Professional Memberships
- Fellow
Hospital Affiliations
- University of Chicago Medical CenterChicago, Illinois
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Coventry Health Care PPO PlatinumCoventry Missouri - HMO/POS
First Health PPO
Great West PPO
HealthLink PPO
Multiplan PHCS PPO
Multiplan PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: